You may be correct however the FDA rejecting a protocol submission and recommending additional changes and resubmittal may not be considered a material event. The definition of a material event is very subjective at best. Knowing what we've seen, or haven't seen, in the last 5 months, I wouldn't expect current mgmt to PR a protocol submittal. It's been several months and they still haven't PR'd the 700mg NASH results.

Quote:

---

a rejection from a regulatory agency has to disclosed to shareholders and it will affect the sp negatively anyway, and vice versa.

---